JP2016523977A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016523977A5 JP2016523977A5 JP2016525491A JP2016525491A JP2016523977A5 JP 2016523977 A5 JP2016523977 A5 JP 2016523977A5 JP 2016525491 A JP2016525491 A JP 2016525491A JP 2016525491 A JP2016525491 A JP 2016525491A JP 2016523977 A5 JP2016523977 A5 JP 2016523977A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- pyridin
- ring
- fluorophenyl
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 -cyclopropyl-OH Chemical group 0.000 claims 88
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 230000035772 mutation Effects 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 3
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 claims 3
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 claims 3
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 102200116484 rs121913502 Human genes 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 claims 2
- 125000006017 1-propenyl group Chemical group 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- HWXBTNAVRSUOJR-UHFFFAOYSA-N 2-hydroxyglutaric acid Chemical compound OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 claims 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 1
- ZCHCHJQEWYIJDQ-UHFFFAOYSA-N 2-methyl-1,3-oxazole Chemical compound CC1=NC=CO1 ZCHCHJQEWYIJDQ-UHFFFAOYSA-N 0.000 claims 1
- SNJKHBIYYOBZOB-UHFFFAOYSA-N 2-n-phenyl-6-pyridin-2-yl-1,3,5-triazine-2,4-diamine Chemical compound N=1C(C=2N=CC=CC=2)=NC(N)=NC=1NC1=CC=CC=C1 SNJKHBIYYOBZOB-UHFFFAOYSA-N 0.000 claims 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 1
- GASCNUBLHQPAMW-UHFFFAOYSA-N 3-[[4-[4-amino-6-(3-chloroanilino)-1,3,5-triazin-2-yl]pyridin-2-yl]amino]propan-1-ol Chemical compound N=1C(C=2C=C(NCCCO)N=CC=2)=NC(N)=NC=1NC1=CC=CC(Cl)=C1 GASCNUBLHQPAMW-UHFFFAOYSA-N 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- WNDZCMWLOVCQCX-UHFFFAOYSA-N 4-(3-chlorophenyl)-6-(2-chloropyridin-4-yl)-1H-1,3,5-triazine-2,4-diamine Chemical compound ClC=1C=C(C=CC=1)C1(NC(=NC(=N1)N)C1=CC(=NC=C1)Cl)N WNDZCMWLOVCQCX-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- VVMOQUNIQBUIAF-UHFFFAOYSA-N 4-pyridin-2-yl-6-pyridin-3-yl-1H-1,3,5-triazine-2,4-diamine Chemical compound N1=C(C=CC=C1)C1(NC(=NC(=N1)N)C=1C=NC=CC=1)N VVMOQUNIQBUIAF-UHFFFAOYSA-N 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- ZXCCTEXFQSKWGV-UHFFFAOYSA-N 6-(2-methoxypyridin-3-yl)-2-n-(4-methylphenyl)-1,3,5-triazine-2,4-diamine Chemical compound COC1=NC=CC=C1C1=NC(N)=NC(NC=2C=CC(C)=CC=2)=N1 ZXCCTEXFQSKWGV-UHFFFAOYSA-N 0.000 claims 1
- OXJGETFIDLHUNV-UHFFFAOYSA-N 6-(6-methoxypyridin-3-yl)-2-n-(4-methylphenyl)-1,3,5-triazine-2,4-diamine Chemical compound C1=NC(OC)=CC=C1C1=NC(N)=NC(NC=2C=CC(C)=CC=2)=N1 OXJGETFIDLHUNV-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- HEIWIFCGAFDAQU-UHFFFAOYSA-N Cc1nccc(n1)-c1nc(N)nc(Nc2cc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)ccc2C)n1 Chemical compound Cc1nccc(n1)-c1nc(N)nc(Nc2cc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)ccc2C)n1 HEIWIFCGAFDAQU-UHFFFAOYSA-N 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 125000003145 oxazol-4-yl group Chemical group O1C=NC(=C1)* 0.000 claims 1
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 claims 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- DNWCRFXHXMDIHP-UHFFFAOYSA-N Nc1nc(NC2CCCCCCCC2)nc(C2CCCCCCCC2)n1 Chemical compound Nc1nc(NC2CCCCCCCC2)nc(C2CCCCCCCC2)n1 DNWCRFXHXMDIHP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361845352P | 2013-07-11 | 2013-07-11 | |
| US61/845,352 | 2013-07-11 | ||
| PCT/US2014/046204 WO2015006592A1 (en) | 2013-07-11 | 2014-07-10 | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016523977A JP2016523977A (ja) | 2016-08-12 |
| JP2016523977A5 true JP2016523977A5 (enExample) | 2017-01-19 |
| JP6471155B2 JP6471155B2 (ja) | 2019-02-13 |
Family
ID=51261261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525491A Active JP6471155B2 (ja) | 2013-07-11 | 2014-07-10 | 癌の治療のためのｉｄｈ２変異体阻害剤としてのｎ，６−ビス（アリール又はヘテロアリール）−１，３，５−トリアジン−２，４−ジアミン化合物 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9724350B2 (enExample) |
| EP (1) | EP3019490B1 (enExample) |
| JP (1) | JP6471155B2 (enExample) |
| KR (1) | KR102302091B1 (enExample) |
| CN (1) | CN105492435B (enExample) |
| AU (1) | AU2014287122B9 (enExample) |
| BR (1) | BR112016000489A8 (enExample) |
| CA (1) | CA2917592A1 (enExample) |
| CL (1) | CL2016000045A1 (enExample) |
| CR (1) | CR20160022A (enExample) |
| EA (1) | EA032070B1 (enExample) |
| ES (1) | ES2807582T3 (enExample) |
| IL (1) | IL243522B (enExample) |
| MX (1) | MX375030B (enExample) |
| MY (1) | MY185687A (enExample) |
| NI (1) | NI201600007A (enExample) |
| NZ (1) | NZ715738A (enExample) |
| PE (1) | PE20160744A1 (enExample) |
| PH (1) | PH12016500055B1 (enExample) |
| SA (1) | SA516370386B1 (enExample) |
| SG (1) | SG11201600058XA (enExample) |
| UA (1) | UA119242C2 (enExample) |
| WO (1) | WO2015006592A1 (enExample) |
| ZA (1) | ZA201600210B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| AU2014287121B2 (en) | 2013-07-11 | 2018-11-15 | Agios Pharmaceuticals, Inc. | 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer |
| SG11201600058XA (en) * | 2013-07-11 | 2016-02-26 | Agios Pharmaceuticals Inc | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
| PE20160840A1 (es) | 2013-08-02 | 2016-09-22 | Agios Pharmaceuticals Inc | Formas cristalinas de compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2) |
| KR20170057411A (ko) | 2014-09-29 | 2017-05-24 | 아지오스 파마슈티컬스 아이엔씨. | 치료적 활성 화합물 및 이들의 사용 방법 |
| KR102628370B1 (ko) | 2015-02-04 | 2024-01-24 | 르 라보레또레 쎄르비에르 | 치료적 활성 화합물 및 이들의 사용 방법 |
| AU2016303614A1 (en) | 2015-08-05 | 2018-02-15 | Agios Pharmaceuticals, Inc. | Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines |
| JP6895956B2 (ja) * | 2015-10-15 | 2021-06-30 | セルジーン コーポレイション | 悪性腫瘍を治療するための併用療法 |
| US10905692B2 (en) | 2015-10-15 | 2021-02-02 | Agios Pharmaceuticals, Inc. | Combination therapy for treating malignancies |
| MA43374A (fr) | 2015-12-04 | 2018-10-10 | Agios Pharmaceuticals Inc | Méthodes de traitement de tumeurs malignes |
| WO2017140758A1 (en) | 2016-02-19 | 2017-08-24 | Debiopharm International S.A. | Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers |
| EP3419593B1 (en) | 2016-02-26 | 2022-03-23 | Celgene Corporation | Enasidenib for use in the treatment of relapsed or refractory acute myeloid leukaemia |
| CN107382840B (zh) * | 2016-05-16 | 2020-09-01 | 四川大学 | 吡啶类化合物及其作为idh功能变异突变体抑制剂类药物的用途 |
| CN107556366B (zh) * | 2016-06-30 | 2025-02-07 | 上海海和药物研究开发股份有限公司 | 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途 |
| CA3029343C (en) * | 2016-07-21 | 2021-02-09 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Chemical compound of isocitrate dehydrogenase inhibitor, and application thereof |
| WO2018026894A1 (en) | 2016-08-03 | 2018-02-08 | Celgene Corporation | Methods of treatment of myelodysplastic syndrome |
| US11389454B2 (en) | 2016-09-07 | 2022-07-19 | Celgene Corporation | Tablet compositions |
| US11229653B2 (en) | 2017-05-05 | 2022-01-25 | Celgene Corporation | Methods of treatment of myeloproliferative neoplasm |
| BR112019028101A2 (pt) | 2017-06-30 | 2020-07-28 | Celgene Corporation | composições e métodos para uso de (2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida) |
| CN109467538A (zh) | 2017-09-07 | 2019-03-15 | 和记黄埔医药（上海）有限公司 | 环烯烃取代的杂芳环类化合物及其用途 |
| CN110054617A (zh) * | 2018-01-19 | 2019-07-26 | 南京圣和药业股份有限公司 | 三嗪类化合物、其制备方法及用途 |
| US12215094B2 (en) | 2018-11-02 | 2025-02-04 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| CN111662242B (zh) * | 2019-03-08 | 2023-10-24 | 中国药科大学 | 杂环类idh突变体抑制剂、其制备方法及用途 |
| CN111087408B (zh) * | 2020-01-03 | 2021-04-02 | 浙江大学 | 一种大环结构的idh2突变体抑制剂及其医药用途 |
| CN112250639B (zh) * | 2020-11-19 | 2022-05-24 | 浙江工业大学 | 一种杂环取代的芳胺类化合物及其制备方法和应用 |
| CN112592958B (zh) * | 2020-12-07 | 2022-11-01 | 山东大学第二医院 | 利用fad依赖型d-2-羟基戊二酸脱氢酶和刃天青检测d-2-羟基戊二酸的方法 |
| CN112645893A (zh) * | 2020-12-28 | 2021-04-13 | 营口昌成新材料科技有限公司 | 一种二卤代均三嗪的合成方法 |
| CN115536637B (zh) * | 2022-10-24 | 2025-03-18 | 陕西中医药大学 | 一种均三嗪类衍生物及其合成方法与用途 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2390529A (en) * | 1942-02-03 | 1945-12-11 | Ernst A H Friedheim | Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds |
| BE754242A (fr) | 1970-07-15 | 1971-02-01 | Geigy Ag J R | Diamino-s-triazines et dinitro-s-triazines |
| US3867383A (en) | 1971-03-29 | 1975-02-18 | Ciba Geigy Corp | Monoanthranilatoanilino-s-triazines |
| JPS5011392B2 (enExample) * | 1971-08-07 | 1975-04-30 | ||
| CH606334A5 (enExample) | 1974-06-21 | 1978-10-31 | Ciba Geigy Ag | |
| JPS58186682A (ja) * | 1982-04-27 | 1983-10-31 | 日本化薬株式会社 | セルロ−ス又はセルロ−ス含有繊維材料の染色法 |
| DE3512630A1 (de) | 1985-04-06 | 1986-10-23 | Hoechst Ag, 6230 Frankfurt | Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern |
| AU665238B2 (en) | 1992-02-28 | 1995-12-21 | Zenyaku Kogyo Kabushiki Kaisha | S-triazine derivative and remedy for estrogen-dependent diseases containing the same as active ingredient |
| GB9602166D0 (en) | 1996-02-02 | 1996-04-03 | Zeneca Ltd | Aminoheterocyclic derivatives |
| CA2271744A1 (en) | 1996-11-14 | 1998-05-22 | Isao Hashiba | Cyanoethylmelamine derivatives and process for producing the same |
| JPH11158073A (ja) | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンａ３拮抗剤 |
| US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| UY25842A1 (es) | 1998-12-16 | 2001-04-30 | Smithkline Beecham Corp | Antagonistas de receptores de il-8 |
| US6274620B1 (en) | 1999-06-07 | 2001-08-14 | Biochem Pharma Inc. | Thiophene integrin inhibitors |
| CA2450934A1 (en) | 2001-06-19 | 2002-12-27 | Marco Dodier | Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
| US7038046B2 (en) | 2001-08-17 | 2006-05-02 | Ciba Specialty Chemicals Corporation | Triazine derivatives and their use as sunscreens |
| JP4753336B2 (ja) | 2001-09-04 | 2011-08-24 | 日本化薬株式会社 | 新規アリル化合物及びその製法 |
| US7291616B2 (en) * | 2001-10-31 | 2007-11-06 | Cell Therapeutics, Inc. | Aryl triazines as LPAAT-β inhibitors and uses thereof |
| US6878196B2 (en) | 2002-01-15 | 2005-04-12 | Fuji Photo Film Co., Ltd. | Ink, ink jet recording method and azo compound |
| EP1546121B1 (en) * | 2002-07-18 | 2012-08-29 | Janssen Pharmaceutica NV | Substituted triazine kinase inhibitors |
| JP2004107220A (ja) | 2002-09-13 | 2004-04-08 | Mitsubishi Pharma Corp | ＴＮＦ−α産生抑制剤 |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| EP1575580A4 (en) | 2002-12-02 | 2009-06-10 | Arqule Inc | METHOD FOR TREATING CARCINOMA |
| EP1590364B1 (en) | 2002-12-16 | 2011-10-05 | Genmab A/S | Human monoclonal antibodies against interleukin 8 (il-8) |
| CA2542031A1 (en) | 2003-10-10 | 2005-04-21 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives for treatment of hyperproliferative disorders |
| US20070196395A1 (en) | 2003-12-12 | 2007-08-23 | Mackerell Alexander | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain |
| KR20070007055A (ko) | 2003-12-24 | 2007-01-12 | 사이오스 인코퍼레이티드 | Ｔｇｆ-베타 억제제를 이용한 악성 신경교종의 치료법 |
| CA2581454A1 (en) | 2004-09-23 | 2006-03-30 | Reddy Us Therapeutics, Inc. | Novel pyrimidine compounds, process for their preparation and compositions containing them |
| AU2006208834A1 (en) | 2005-01-25 | 2006-08-03 | Astrazeneca Ab | Chemical compounds |
| US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| TW200815426A (en) | 2006-06-28 | 2008-04-01 | Astrazeneca Ab | New pyridine analogues II 333 |
| US20100234341A1 (en) | 2006-12-04 | 2010-09-16 | Marion Lanier | Substituted pyrimidines as adenosine receptor antagonists |
| WO2008076883A2 (en) | 2006-12-15 | 2008-06-26 | Abraxis Bioscience, Inc. | Triazine derivatives and their therapeutical applications |
| WO2008131547A1 (en) | 2007-04-30 | 2008-11-06 | Prometic Biosciences Inc. | 'triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives' |
| AU2008262291A1 (en) | 2007-06-11 | 2008-12-18 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
| BRPI0818366A2 (pt) | 2007-10-10 | 2015-04-07 | Takeda Pharmaceutical | Composto, pró-droga, medicamento, método inibidor de faah, métodos de profilaxia ou tratamento para ansiedade, ou depressão, ou de alívio da dor, e de profilaxia ou tratamento para dor inflamatória ou dor neuropática, e, uso do composto. |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| GB0805477D0 (en) * | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| JP5277685B2 (ja) | 2008-03-26 | 2013-08-28 | 富士ゼロックス株式会社 | 電子写真感光体、画像形成装置、プロセスカートリッジ及び画像形成方法 |
| CN101575408B (zh) | 2008-05-09 | 2013-10-30 | Mca技术有限公司 | 用作阻燃剂和光稳定剂的聚三嗪基化合物 |
| WO2010028179A1 (en) | 2008-09-03 | 2010-03-11 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds as gata modulators |
| JP2010079130A (ja) | 2008-09-29 | 2010-04-08 | Fuji Xerox Co Ltd | 電子写真感光体、プロセスカートリッジ、及び画像形成装置 |
| JP2010181540A (ja) | 2009-02-04 | 2010-08-19 | Fuji Xerox Co Ltd | 電子写真感光体、プロセスカートリッジ、及び画像形成装置 |
| KR101677778B1 (ko) | 2009-02-06 | 2016-11-18 | 니뽄 신야쿠 가부시키가이샤 | 아미노피라진 유도체 및 의약 |
| JP6067226B2 (ja) | 2009-03-13 | 2017-01-25 | アジオス ファーマシューティカルズ， インコーポレイテッド | 細胞増殖関連疾患のための方法および組成物 |
| WO2010144338A1 (en) | 2009-06-08 | 2010-12-16 | Abraxis Bioscience, Llc | Triazine derivatives and their therapeutical applications |
| AU2010258974A1 (en) | 2009-06-09 | 2012-01-12 | California Capital Equity, Llc | Pyridil-triazine inhibitors of hedgehog signaling |
| BRPI1011527A2 (pt) | 2009-06-09 | 2016-07-26 | California Capital Equity Llc | derivados de triazina substituídos com ureidofenil e suas aplicações terapêuticas. |
| WO2011005208A1 (en) | 2009-07-10 | 2011-01-13 | Milux Holding S.A. | Knee joint device and method |
| JP5473851B2 (ja) | 2009-09-30 | 2014-04-16 | 富士フイルム株式会社 | 高分子フィルム、位相差フィルム、偏光板及び液晶表示装置 |
| ES2594402T3 (es) | 2009-10-21 | 2016-12-20 | Agios Pharmaceuticals, Inc. | Métodos y composiciones para trastornos relacionados con la proliferación celular |
| WO2011050211A2 (en) | 2009-10-21 | 2011-04-28 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| JP5967827B2 (ja) | 2009-12-09 | 2016-08-10 | アジオス ファーマシューティカルズ， インコーポレイテッド | Ｉｄｈ変異体をもつことを特徴とする癌治療用の治療的活性化合物 |
| US20130197106A1 (en) | 2010-04-01 | 2013-08-01 | Agios Pharmaceuticals, Inc | Methods of identifying a candidate compound |
| BR112013001122B1 (pt) | 2010-07-16 | 2021-06-08 | Agios Pharmaceuticals, Inc | composto de fórmula ii, uso do composto e composição farmacêutica compreendendo dito composto |
| JP5907986B2 (ja) | 2010-11-29 | 2016-04-26 | ガリオン ファーマシューティカルズ インコーポレイテッド | 呼吸制御障害または呼吸制御疾患の処置用の呼吸刺激薬としての化合物 |
| EP2691391A4 (en) | 2011-03-29 | 2014-09-10 | Broad Inst Inc | COMPOUNDS AND METHODS OF TREATING DISORDERS MEDIATED BY ISOCITRATE DEHYDROGENASE |
| CN102250065B (zh) * | 2011-05-20 | 2015-05-13 | 浙江海正药业股份有限公司 | 取代的三嗪苯脲衍生物及其用途 |
| TW201636330A (zh) | 2011-05-24 | 2016-10-16 | 拜耳知識產權公司 | 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺 |
| CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN102659765B (zh) | 2011-12-31 | 2014-09-10 | 沈阳药科大学 | 嘧啶及三嗪类化合物的制备方法和应用 |
| CA2860623A1 (en) * | 2012-01-06 | 2013-07-11 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2013107405A1 (en) | 2012-01-19 | 2013-07-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| EP2824099A4 (en) | 2012-03-09 | 2015-11-11 | Carna Biosciences Inc | NOVEL TRIAZINE DERIVATIVE |
| SG11201600058XA (en) * | 2013-07-11 | 2016-02-26 | Agios Pharmaceuticals Inc | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
-
2014
- 2014-07-10 SG SG11201600058XA patent/SG11201600058XA/en unknown
- 2014-07-10 EA EA201690204A patent/EA032070B1/ru not_active IP Right Cessation
- 2014-07-10 ES ES14745309T patent/ES2807582T3/es active Active
- 2014-07-10 WO PCT/US2014/046204 patent/WO2015006592A1/en not_active Ceased
- 2014-07-10 AU AU2014287122A patent/AU2014287122B9/en active Active
- 2014-07-10 US US14/904,032 patent/US9724350B2/en active Active
- 2014-07-10 MY MYPI2016700044A patent/MY185687A/en unknown
- 2014-07-10 BR BR112016000489A patent/BR112016000489A8/pt not_active Application Discontinuation
- 2014-07-10 NZ NZ715738A patent/NZ715738A/en unknown
- 2014-07-10 KR KR1020167003352A patent/KR102302091B1/ko active Active
- 2014-07-10 PE PE2016000042A patent/PE20160744A1/es unknown
- 2014-07-10 JP JP2016525491A patent/JP6471155B2/ja active Active
- 2014-07-10 MX MX2016000336A patent/MX375030B/es active IP Right Grant
- 2014-07-10 EP EP14745309.6A patent/EP3019490B1/en active Active
- 2014-07-10 CN CN201480047026.XA patent/CN105492435B/zh active Active
- 2014-07-10 CA CA2917592A patent/CA2917592A1/en not_active Abandoned
- 2014-10-07 UA UAA201601118A patent/UA119242C2/uk unknown
-
2016
- 2016-01-07 IL IL243522A patent/IL243522B/en active IP Right Grant
- 2016-01-07 PH PH12016500055A patent/PH12016500055B1/en unknown
- 2016-01-08 NI NI201600007A patent/NI201600007A/es unknown
- 2016-01-11 SA SA516370386A patent/SA516370386B1/ar unknown
- 2016-01-11 CR CR20160022A patent/CR20160022A/es unknown
- 2016-01-11 CL CL2016000045A patent/CL2016000045A1/es unknown
- 2016-01-11 ZA ZA2016/00210A patent/ZA201600210B/en unknown
-
2017
- 2017-06-22 US US15/630,886 patent/US10111878B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016523977A5 (enExample) | ||
| ES2675760T3 (es) | Compuestos terapéuticamente activos y métodos de uso de los mismos | |
| RU2015100942A (ru) | Производное пиперидинилпиразолпиридина | |
| JP2015503571A5 (enExample) | ||
| JP2017075193A5 (enExample) | ||
| RU2015132181A (ru) | Фтор-[1,3]-оксазины в качестве ингибиторов васе1 | |
| RU2012105284A (ru) | Спиро-аминосоединения, пригодные для лечения нарушений сна и лекарственного привыкания | |
| RU2018138050A (ru) | Производные тиазолопиридина как агонисты gpr119 | |
| CN110139860A (zh) | 1,3,5-三嗪衍生物的盐及其晶体、它们的制备方法、药物组合物和用途 | |
| HRP20212000T1 (hr) | Aminotriazolopiridini kao inhibitori kinaze | |
| RU2018138047A (ru) | Гетероциклические вещества - агонисты gpr119 | |
| JP2017511329A5 (enExample) | ||
| JP2016525075A5 (enExample) | ||
| JP2016523935A5 (enExample) | ||
| RU2012126989A (ru) | 2-амино-5,5-дифтор-5,6-дигидро-4н-оксазины в качестве ингибиторов васе 1 и(или) васе 2 | |
| JP2012525395A5 (enExample) | ||
| JP2016522231A5 (enExample) | ||
| JP2016523976A5 (enExample) | ||
| JP2008519765A5 (enExample) | ||
| JP2016522232A5 (enExample) | ||
| JP2011503230A5 (enExample) | ||
| JP2015526452A5 (enExample) | ||
| JP2017527631A5 (enExample) | ||
| JP2014510147A5 (enExample) | ||
| RU2018131775A (ru) | 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета |